Patient characteristics according to PCI-related delay and randomised study treatment
| PCI-related delay | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| ≤55 min (n=583) | >55–97 min (n=711) | >97 min (n=359) | |||||||
| All | PI | P-PCI | All | PI | P-PCI | All | PI | P-PCI | |
| n | 583 | 288 | 295 | 711 | 359 | 352 | 359 | 179 | 180 |
| Age, years | 58 (50–66) | 59 (49–66) | 57 (51–66) | 60 (52–71) | 60 (52–72) | 60 (51–70) | 59 (50–69)* | 60 (50–68) | 59 (50–70) |
| Women, % | 17.8 | 17.4 | 18.3 | 24.6 | 24.5 | 24.7 | 24.0* | 21.8 | 26.1 |
| Weight, kg | 80 (70–90) | 80 (70–90) | 80 (70–90) | 80 (70–90) | 80 (70–90) | 80 (70–90) | 80 (70–88) | 80 (70–90) | 80 (70–86) |
| Hypertension, % | 42.2 | 42.7 | 41.6 | 48.9 | 51.4 | 46.3 | 45.3 | 44.0 | 46.6 |
| Diabetes mellitus, % | 12.9 | 13.6 | 12.1 | 10.1 | 9.3 | 10.9 | 18.4 | 16.5 | 20.2 |
| Previous MI, % | 9.8 | 7.7 | 11.9 | 9.6 | 10.3 | 8.8 | 10.3 | 9.0 | 11.7 |
| Previous CHF, % | 0.7 | 0.4 | 1.0 | 0.9 | 0.3 | 1.4 | 1.4 | 0.0 | 2.8† |
| Previous PCI, % | 8.4 | 5.9 | 10.9† | 7.2 | 7.8 | 6.6 | 7.5 | 5.6 | 9.4 |
| Heart rate, bpm | 72 (61–85) | 72 (60–85) | 72 (62–85) | 75 (62–85) | 75 (60–86) | 75 (64–85) | 76 (65–89)* | 76 (67–89) | 76 (65–89) |
| Systolic blood pressure, mm Hg | 137 (120–152) | 137 (119–150) | 136 (120–154) | 137 (120–150) | 132 (120–150) | 140 (120–150) | 130 (120–147) | 130 (120–147) | 130 (120–149) |
| Inferior infarct location, % | 50.5 | 49.5 | 51.5 | 49.8 | 47.9 | 51.7 | 52.8 | 52.3 | 53.3 |
| Q-wave, % | 32.3 | 32.2 | 32.4 | 32.1 | 30.8 | 33.3 | 32.2 | 34.3 | 30.2 |
| Sum ST-deviation, mm | 14.5 (9.5–20.5) | 15.0 (9.0–21.5) | 13.8 (9.5–19.0) | 13.0 (9.0–19.0) | 13.0 (9.0–19.0) | 13.5 (8.8–19.0) | 13.0 (9.0–19.0)* | 13.3 (9.0–19.5) | 13 (8.5–19.0) |
| Killip class >I, % | 4.6 | 6.1 | 3.0 | 4.3 | 2.3 | 6.2 | 8.7* | 10.1 | 7.3 |
| TIMI risk score≥5, % | 10.8 | 10.3 | 11.2 | 14.7 | 15.1 | 14.2 | 17.7* | 17.1 | 18.3 |
| Symptom onset to first medial contact, min | 50 (30–85) | 52 (30–84) | 50 (30–86) | 65 (45–104) | 65 (46–100) | 67 (42–105) | 79 (44–120)* | 81 (45–120) | 74 (40–115) |
| First medical contact to randomisation, min | 26 (19–33) | 25 (18–32) | 26 (30–34) | 22 (17–30) | 22 (16–31) | 23 (17–30) | 27 (17–38)* | 27 (15–38) | 27 (20–37) |
| Symptom onset to randomisation, min | 80 (56–115) | 79 (58–115) | 81 (55–118) | 93 (71–132) | 91 (71–132) | 96 (71–133) | 114 (76–153)* | 116 (75–153) | 113 (78–151) |
| Symptom onset to start of reperfusion therapy, min | 115 (81–155) | 90 (65–125) | 135 (105–175)† | 145 (96–190) | 100 (80–140) | 185 (152–235)† | 178 (130–235)* | 130 (85–165) | 235 (200–275)† |
| Randomisation to start of reperfusion therapy, min | 28 (9–53) | 9 (7–14) | 52 (42–63)† | 29 (8–88) | 8 (5–12) | 88 (66–111)† | 39 (10–120)* | 10 (7–15) | 120 (105–138)† |
*p<0.05 for test for trend across P-RD.
†p<0.05 for study treatment-wise comparisons within P-RD category.
CHF, congestive heart failure; MI, myocardial infarction; PI, pharmacoinvasive; P-PCI, primary percutaneous coronary intervention; P-RD, PCI-related delay; TIMI, Thrombolysis In Myocardial Infarction.